Product
Amphotericin B liposome
1 clinical trial
1 indication
Indication
bioequivalenceClinical trial
A Randomized, Open-label, Single-dose, Two-preparation, Two-period, Two-sequence Bioequivalence Study Between Amphotericin B Liposome for Injection and AmBisome® in Healthy SubjectsStatus: Completed, Estimated PCD: 2023-09-01